Clopidogrel Prescribing and Concordance with the Pharmaceutical Benefits Scheme in Hospital Patients

M LUINSTRA, Mark Naunton, N K PETERSON, L BEREZNICKI

    Research output: Contribution to journalArticleResearchpeer-review

    Abstract

    Background: Clopidogrel is used for the secondary prevention of cerebrovascular and cardiovascular events. Clopidogrel has a similar safety profile to low-dose aspirin but is considerably more expensive. Clopidogrel is subsidised for restricted indications via the Pharmaceutical Benefits Scheme (PBS). Aim: To examine clopidogrel prescribing in hospital; and to identify patients discharged on clopidogrel according to PBS criteria. Method: Cross-sectional evaluation of patients started on clopidogrel (July 2006 to June 2007) at the Royal Darwin and Royal Hobart Hospitals. Clopidogrel prescribing was examined and the indication for discharge on clopidogrel was documented. The primary outcome was concordance between clopidogrel use and PBS criteria. Results: Data were collected for 385 patients. 54% of patients from the Royal Darwin Hospital and 39% of patients from the Royal Hobart Hospital discharged on clopidogrel met PBS criteria. The main reason for noncompliance with the PBS was absence of a history of cardiovascular or cerebrovascular events while on low-dose aspirin and an absence of contraindications to aspirin at the time of clopidogrel prescribing. Conclusion: Although clopidogrel prescribing at the hospitals was often not in accordance with PBS criteria, in most cases prescribing was based on the available evidence.
    Original languageEnglish
    Pages (from-to)265-268
    Number of pages4
    JournalJournal of Pharmacy Practice and Research
    Volume39
    Issue number4
    Publication statusPublished - 2009

    Fingerprint

    clopidogrel
    Pharmaceutical Preparations
    Aspirin

    Cite this

    LUINSTRA, M ; Naunton, Mark ; PETERSON, N K ; BEREZNICKI, L. / Clopidogrel Prescribing and Concordance with the Pharmaceutical Benefits Scheme in Hospital Patients. In: Journal of Pharmacy Practice and Research. 2009 ; Vol. 39, No. 4. pp. 265-268.
    @article{6bfff5761d8a4063b5653db0aadba160,
    title = "Clopidogrel Prescribing and Concordance with the Pharmaceutical Benefits Scheme in Hospital Patients",
    abstract = "Background: Clopidogrel is used for the secondary prevention of cerebrovascular and cardiovascular events. Clopidogrel has a similar safety profile to low-dose aspirin but is considerably more expensive. Clopidogrel is subsidised for restricted indications via the Pharmaceutical Benefits Scheme (PBS). Aim: To examine clopidogrel prescribing in hospital; and to identify patients discharged on clopidogrel according to PBS criteria. Method: Cross-sectional evaluation of patients started on clopidogrel (July 2006 to June 2007) at the Royal Darwin and Royal Hobart Hospitals. Clopidogrel prescribing was examined and the indication for discharge on clopidogrel was documented. The primary outcome was concordance between clopidogrel use and PBS criteria. Results: Data were collected for 385 patients. 54{\%} of patients from the Royal Darwin Hospital and 39{\%} of patients from the Royal Hobart Hospital discharged on clopidogrel met PBS criteria. The main reason for noncompliance with the PBS was absence of a history of cardiovascular or cerebrovascular events while on low-dose aspirin and an absence of contraindications to aspirin at the time of clopidogrel prescribing. Conclusion: Although clopidogrel prescribing at the hospitals was often not in accordance with PBS criteria, in most cases prescribing was based on the available evidence.",
    keywords = "acetylsalicylic acid, clopidogrel, adult, aged, article, cardiovascular disease, cerebrovascular disease, clinical evaluation, clinical trial, controlled study, cross-sectional study, drug contraindication, drug industry, female, hospital discharge, hospital patient, human, low drug dose, major clinical study, male, multicenter study, outcome assessment, prescription, secondary prevention, treatment indication, treatment outcome, treatment refusal",
    author = "M LUINSTRA and Mark Naunton and PETERSON, {N K} and L BEREZNICKI",
    year = "2009",
    language = "English",
    volume = "39",
    pages = "265--268",
    journal = "Journal of Pharmacy Practice and Research",
    issn = "0310-6810",
    publisher = "Society of Hospital Pharmacists of Australia",
    number = "4",

    }

    LUINSTRA, M, Naunton, M, PETERSON, NK & BEREZNICKI, L 2009, 'Clopidogrel Prescribing and Concordance with the Pharmaceutical Benefits Scheme in Hospital Patients', Journal of Pharmacy Practice and Research, vol. 39, no. 4, pp. 265-268.

    Clopidogrel Prescribing and Concordance with the Pharmaceutical Benefits Scheme in Hospital Patients. / LUINSTRA, M; Naunton, Mark; PETERSON, N K; BEREZNICKI, L.

    In: Journal of Pharmacy Practice and Research, Vol. 39, No. 4, 2009, p. 265-268.

    Research output: Contribution to journalArticleResearchpeer-review

    TY - JOUR

    T1 - Clopidogrel Prescribing and Concordance with the Pharmaceutical Benefits Scheme in Hospital Patients

    AU - LUINSTRA, M

    AU - Naunton, Mark

    AU - PETERSON, N K

    AU - BEREZNICKI, L

    PY - 2009

    Y1 - 2009

    N2 - Background: Clopidogrel is used for the secondary prevention of cerebrovascular and cardiovascular events. Clopidogrel has a similar safety profile to low-dose aspirin but is considerably more expensive. Clopidogrel is subsidised for restricted indications via the Pharmaceutical Benefits Scheme (PBS). Aim: To examine clopidogrel prescribing in hospital; and to identify patients discharged on clopidogrel according to PBS criteria. Method: Cross-sectional evaluation of patients started on clopidogrel (July 2006 to June 2007) at the Royal Darwin and Royal Hobart Hospitals. Clopidogrel prescribing was examined and the indication for discharge on clopidogrel was documented. The primary outcome was concordance between clopidogrel use and PBS criteria. Results: Data were collected for 385 patients. 54% of patients from the Royal Darwin Hospital and 39% of patients from the Royal Hobart Hospital discharged on clopidogrel met PBS criteria. The main reason for noncompliance with the PBS was absence of a history of cardiovascular or cerebrovascular events while on low-dose aspirin and an absence of contraindications to aspirin at the time of clopidogrel prescribing. Conclusion: Although clopidogrel prescribing at the hospitals was often not in accordance with PBS criteria, in most cases prescribing was based on the available evidence.

    AB - Background: Clopidogrel is used for the secondary prevention of cerebrovascular and cardiovascular events. Clopidogrel has a similar safety profile to low-dose aspirin but is considerably more expensive. Clopidogrel is subsidised for restricted indications via the Pharmaceutical Benefits Scheme (PBS). Aim: To examine clopidogrel prescribing in hospital; and to identify patients discharged on clopidogrel according to PBS criteria. Method: Cross-sectional evaluation of patients started on clopidogrel (July 2006 to June 2007) at the Royal Darwin and Royal Hobart Hospitals. Clopidogrel prescribing was examined and the indication for discharge on clopidogrel was documented. The primary outcome was concordance between clopidogrel use and PBS criteria. Results: Data were collected for 385 patients. 54% of patients from the Royal Darwin Hospital and 39% of patients from the Royal Hobart Hospital discharged on clopidogrel met PBS criteria. The main reason for noncompliance with the PBS was absence of a history of cardiovascular or cerebrovascular events while on low-dose aspirin and an absence of contraindications to aspirin at the time of clopidogrel prescribing. Conclusion: Although clopidogrel prescribing at the hospitals was often not in accordance with PBS criteria, in most cases prescribing was based on the available evidence.

    KW - acetylsalicylic acid

    KW - clopidogrel

    KW - adult

    KW - aged

    KW - article

    KW - cardiovascular disease

    KW - cerebrovascular disease

    KW - clinical evaluation

    KW - clinical trial

    KW - controlled study

    KW - cross-sectional study

    KW - drug contraindication

    KW - drug industry

    KW - female

    KW - hospital discharge

    KW - hospital patient

    KW - human

    KW - low drug dose

    KW - major clinical study

    KW - male

    KW - multicenter study

    KW - outcome assessment

    KW - prescription

    KW - secondary prevention

    KW - treatment indication

    KW - treatment outcome

    KW - treatment refusal

    M3 - Article

    VL - 39

    SP - 265

    EP - 268

    JO - Journal of Pharmacy Practice and Research

    JF - Journal of Pharmacy Practice and Research

    SN - 0310-6810

    IS - 4

    ER -